Insulin aspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes.[17] It is generally used by injection under the skin but may also be used by injection into a vein.[17] Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours.[17] Generally a longer-acting insulin like insulin NPH is also needed.[17]
Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection.[17] Other serious side effects may include low blood potassium.[17] Use in pregnancy and breastfeeding is generally safe.[4] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[17] It is a manufactured form of human insulin; where a single amino acid has been changed, specifically a proline with an aspartic acid at the B28 position.[18]
Insulin aspart was approved for medical use in the United States in 2000.[17] In 2021, it was the 71st most commonly prescribed medication in the United States, with more than 9million prescriptions.[19][20] Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome.[21] This yeast then makes the insulin, which is harvested from the bioreactor.[22]
^ abCite error: The named reference Kirsty EPAR was invoked but never defined (see the help page).
^"Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
^ abcCite error: The named reference Truvelog APMDS was invoked but never defined (see the help page).
^ ab"Insulin aspart Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
^ ab"Australian Public Assessment Report for Insulin aspart" (PDF). Therapeutic Goods Administration (TGA). March 2021. Archived from the original (PDF) on 24 June 2021.
^"Australian Public Assessment Report for Insulin aspart (rys)" (PDF). Therapeutic Goods Administration (TGA). August 2021. Archived from the original (PDF) on 5 February 2022.
^Cite error: The named reference Truvelog Solostar ARTG was invoked but never defined (see the help page).
^"Regulatory Decision Summary - Fiasp". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
^"Regulatory Decision Summary - Trurapi". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
^"Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^Cite error: The named reference NovoRapid SmPC was invoked but never defined (see the help page).
^"Fiasp- insulin aspart injection injection, solution". DailyMed. 19 December 2019. Archived from the original on 13 November 2020. Retrieved 12 November 2020.
^"NovoLog- insulin aspart injection, solution Insulin Diluting Medium For NovoLog- water injection injection, solution". DailyMed. 15 November 2019. Archived from the original on 12 November 2020. Retrieved 12 November 2020.
^"NovoLog Mix 70/30- insulin aspart injection, suspension". DailyMed. 15 November 2019. Archived from the original on 29 September 2020. Retrieved 12 November 2020.
^Cite error: The named reference NovoMix EPAR was invoked but never defined (see the help page).
^Cite error: The named reference Truvelog Mix 30 EPAR was invoked but never defined (see the help page).
^ abcdefgh"Insulin Aspart Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
^Turner JR (2010). New Drug Development: An Introduction to Clinical Trials: Second Edition. Springer Science & Business Media. p. 32. ISBN 9781441964182. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
^"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^"Insulin Aspart - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
^Banga AK (2005). Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Second Edition. CRC Press. p. 13. ISBN 9781420039832. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
^Schmid RD, Schmidt-Dannert C (2016). Biotechnology: An Illustrated Primer. John Wiley & Sons. p. 222. ISBN 9783527677566. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
Insulinaspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is...
from insulinaspart. This 2-component insulin retains the ultralow risk characteristics of degludec with simultaneous mealtime coverage. Insulin degludec...
Insulin icodec, sold under the brand name Awiqli, is a medication used for the treatment of diabetes to improve glycemic control. It is an ultralong-acting...
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type I and...
modifications in that region accounts for common insulin analogs with C-terminal modifications (e.g. lispro, aspart, glulisine). The Genentech synthesis and completely...
and time in hypoglycemia in adults with Type I diabetes, compared to insulinAspart. Neumiller, Joshua (June 2010). "Pharmacologist". Annals of Pharmacotherapy...
injections. Novo Nordisk created "aspart" and marketed it as NovoLog/NovoRapid (UK-CAN) as a rapid-acting insulin analogue. It was created through recombinant...
to enhance growth of pancreatic beta cells, which are responsible for insulin production and release. Additionally, it inhibits the production of glucagon...
receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Common...
effective in reducing insulin resistance, with a reduction of around 8% from baseline, measured using HOMA2-IR (computed with fasting insulin). Fasting levels...
diabetes; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately...
It works by decreasing glucose production in the liver, increasing the insulin sensitivity of body tissues, and increasing GDF15 secretion, which reduces...
being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be...
Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting insulin given to help control blood sugar levels in...
Regular insulin, also known as neutral insulin and soluble insulin, is a type of short-acting medical insulin. It is used to treat type 1 diabetes, type...
gliflozins cause less stimulation of endogenous insulin secretion or lower dose of exogenous insulin that results in diabetic ketoacidosis. They can specifically...
increasing secretion of insulin from the beta cells in the pancreas. Sulfonylureas are ineffective where there is absolute deficiency of insulin production such...
risk of low blood sugar when it is used together with a sulfonylurea or insulin. When used by itself or in addition to metformin it does not appear to...
peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. Sitagliptin...
"Insulin formulations--a review". European Review for Medical and Pharmacological Sciences. 5 (3): 73–83. PMID 12004916. #Insulinaspart "Insulin human"...
sulfonylurea family of medications. It works mostly by increasing the release of insulin. Gliclazide was patented in 1966 and approved for medical use in 1972....
Global Information
(what is this?) (verify)